Our Team

Evox_Team_Photo.jpg

Founders

The scientific founders and advisors of Evox are world-leading exosome scientists and physicians, with expertise in all aspects from exosome biology and purification to targeted drug delivery systems and treatment of rare life-threatening diseases.

IMG_8706.jpg

Matthew Wood, MD, PhD

Co-Founder

Co-founder of Evox, Professor of Neuroscience in the Department of Physiology, Anatomy and Genetics at the University of Oxford, as well as Associate Head of the Medical Sciences Division responsible for Research. Professor Wood has a distinguished international profile and co-leads several research initiatives, with a particular focus on neuromuscular diseases.

IMG_8715.jpg

Dr Per Lundin

Co-founder of Evox, Chief Operating Officer and acting CEO

European Patent Attorney with considerable business development and IP strategy experience. Previously at Thomson Reuters IP & Science; founder and CEO of IsletOne Therapeutics, a cell therapy company spun out from the Karolinska Institute; patent attorney in private practice. Started his career as scientist within nanoparticle drug delivery with Australian biotech company Apollo Life Sciences. PhD from the Karolinska Institute, MBA from Stockholm University.

IMG_8701.jpg

Assistant Professor Samir EL Andaloussi

Co-founder of Evox, Research Fellow at Oxford University and Assistant Professor at Karolinska Institutet

Focuses his academic research on exosome-based delivery of biomacromolecules. Previously postdoctal researchers in the Wood lab. Holds a PhD in neurochemistry from Stockholm University.

 

Executive Leadership

Evox has assembled a driven management team with a broad and deep range of skills and experiences across scientific and clinical development and commercial operations. We are building a mission-driven biotechnology company with innovation, collaboration, diversity and excellence as our core values.

IMG_8702.jpg

Dr Antonin de Fougerolles 

Chief Executive Officer

Tony has over 20 years’ experience in the pharmaceutical and biotechnology industry. He has a strong background in successfully developing and advancing multiple different transformative therapeutic drug platforms in both the nucleic acid and biologics space. In addition, his in-depth expertise in drug development has led to the progression of multiple assets through clinical trials, as well as playing a key role in the negotiation of major partnerships. Prior to joining Evox Therapeutics, Tony was CSO at Ablynx NV and Moderna Therapeutics, and VP Research at Alnylam Pharmaceuticals. PhD in Immunology from Harvard University.

IMG_8715.jpg

Dr Per Lundin

Chief Operating Officer

European Patent Attorney with considerable business development and IP strategy experience. Previously at Thomson Reuters IP & Science; founder and CEO of IsletOne Therapeutics, a cell therapy company spun out from the Karolinska Institute; patent attorney in private practice. Started his career as scientist within nanoparticle drug delivery with Australian biotech company Apollo Life Sciences. PhD from the Karolinska Institute, MBA from Stockholm University.